journal
preproof
j
u
r
n
l
p
r
e
p
r
f
j
u
r
n
l
p
r
e
p
r
f
upper
respiratori
tract
infect
urti
includ
rhiniti
nasopharyng
tonsil
otiti
media
caus
urti
mostli
viral
eg
rhinoviru
parainfluenza
respiratori
syncyti
viru
influenza
adenoviru
corona
viru
children
suscept
urti
immun
system
fulli
matur
increas
exposur
viral
infect
social
environment
factor
tonsil
inflamm
pharyng
tonsil
inflamm
usual
reach
adenoid
lingual
tonsil
term
tonsillopharyng
usual
use
recurr
tonsil
defin
repeat
attack
acut
tonsil
period
without
symptom
recurr
tonsil
sequela
complic
includ
sever
lower
tract
infect
need
surgeri
high
impact
famili
daili
life
healthcar
cost
owe
high
morbid
mortal
healthcar
cost
effect
prevent
treatment
need
tonsillectomi
usual
indic
patient
acut
tonsil
attack
last
month
recommend
patient
less
attack
tonsillectomi
associ
signific
risk
primari
secondari
hemorrhag
addit
pain
procedur
also
tonsillectomi
may
affect
patient
immun
system
signific
decreas
interleukin
immunoglobulin
level
postop
recent
studi
recommend
random
control
trial
adequ
longterm
followup
clarifi
benefit
tonsillectomi
versu
nonsurg
treatment
patient
recurr
tonsil
drug
penicillin
azithromycin
azt
wide
use
control
recurr
tonsil
sirimanna
et
al
report
use
longact
penicillin
recurr
tonsil
prevent
howev
longterm
use
penicillin
may
result
hypersensit
reaction
j
u
r
n
l
p
r
e
p
r
f
gopal
et
al
report
use
mg
weekli
oral
azt
effect
prevent
streptococc
throat
infect
compar
oral
penicillin
therapi
american
indian
first
use
echinacea
plant
found
central
southwestern
america
mani
differ
condit
includ
cough
sore
throat
tonsil
differ
speci
echinacea
exist
echinacea
purpurea
echinacea
pallida
echinacea
angustifolia
regularli
use
treat
common
cold
echinacea
use
north
america
peak
earli
use
sharpli
declin
advent
antibiot
denounc
wellrespect
medic
journal
recent
surg
use
herbal
remedi
spend
echinacea
unit
state
risen
million
year
aim
studi
assess
effect
combin
use
oral
azt
plu
echinacea
compar
exclus
use
azt
children
recurr
tonsil
regard
rate
tonsil
attack
sever
tonsil
symptom
j
u
r
n
l
p
r
e
p
r
f
prospect
random
clinic
trial
conduct
period
march
march
approv
committe
medic
research
ethic
egypt
registr
number
patient
parent
sign
written
consent
prior
inclus
studi
pharmaceut
compani
fund
studi
contribut
studi
design
outcom
evalu
write
studi
total
pediatr
patient
elig
enrol
studi
children
attend
ent
outpati
clinic
recurr
tonsil
indic
tonsillectomi
defin
least
episod
acut
tonsil
previou
year
episod
previou
two
year
episod
preced
year
inclus
studi
includ
clinic
signific
sore
throat
defin
acut
tonsil
one
follow
featur
greater
degre
c
lymphadenopathi
tender
cervic
lymph
node
node
exud
posit
cultur
group
bhemolyt
streptococcu
gabh
sex
age
rang
year
includ
block
random
scheme
use
computergener
random
number
perform
divid
children
group
group
patient
nt
receiv
prophylact
treatment
group
patient
receiv
prophylact
dose
azt
mgkg
administ
mgkgday
azt
administ
oral
suspens
ml
young
children
mg
tablet
older
children
maximum
adult
daili
dose
mg
taken
singl
daili
dose
hour
meal
consecut
day
everi
month
consecut
month
group
patient
receiv
azt
group
plu
commerci
avail
echinacea
dose
oral
suspens
time
daili
consecut
day
everi
month
consecut
month
contain
mg
echinacea
root
powder
extract
standard
nlt
total
phenol
patient
group
receiv
commerci
avail
echinacea
product
complianc
assess
patient
diari
card
basi
calcul
amount
drug
consum
j
u
r
n
l
p
r
e
p
r
f
exclud
studi
patient
follow
heart
diseas
receiv
longact
penicillin
mellitu
diseas
take
immunosuppress
drug
organ
transplant
suffer
hepat
renal
disord
histori
obstruct
sleep
apnea
children
underw
complet
oral
nasal
examin
assess
complet
medic
histori
patient
includ
number
tonsil
attack
sever
record
tonsil
symptom
month
enrol
studi
compar
month
studi
durat
relev
questionnair
complet
patient
parent
younger
children
older
children
assess
recurr
tonsil
symptom
eg
number
school
absenc
day
dysphagia
fever
bodi
ach
arthralagia
use
visual
analogu
score
va
assess
subject
symptom
symptom
sever
andor
constant
symptom
side
effect
use
drug
record
compar
statist
packag
social
scienc
version
spss
chicago
illinoi
usa
use
data
analysi
quantit
data
present
mean
standard
deviat
mannwhitney
nonparametr
test
ttest
appli
compar
group
respect
differ
variabl
fisher
exact
test
use
determin
differ
level
complianc
probabl
use
cutoff
point
signific
test
total
children
recurr
tonsil
male
femal
age
year
mean
age
year
randomli
divid
group
assess
efficaci
new
adopt
prophylact
treatment
regiemen
follow
group
n
children
prophylact
treatment
wherea
group
n
children
receiv
oral
azt
group
children
receiv
oral
azt
plu
oral
echinacea
enrol
patient
group
statist
signific
differ
respect
age
gender
weight
tabl
mean
intens
tonsil
symptom
accord
va
treatment
among
group
summar
tabl
ii
statist
signific
differ
differ
group
group
patient
statist
signific
differ
regard
number
tonsil
attack
studi
durat
compar
prestudi
durat
p
patient
signific
less
number
tonsil
attack
studi
durat
compar
prestudi
durat
p
group
patient
signific
less
number
tonsil
attack
studi
durat
compar
prestudi
durat
p
patient
group
signific
less
number
tonsil
attack
studi
durat
compar
patient
group
ii
p
mean
intens
differ
tonsil
symptom
accord
va
treatment
studi
group
summar
tabl
ii
six
month
start
studi
tabl
iii
tonsillectomi
common
pediatr
oper
howev
effect
safeti
net
benefit
tonsillectomi
unclear
tonsillectomi
morbid
high
impact
qol
patient
socioeconom
factor
increas
burden
parent
suffer
child
tonsillectomi
solut
possibl
immunolog
deficit
function
tonsil
immun
system
complet
clear
import
constitu
upper
respiratori
tract
defens
system
hand
patient
undergon
tonsillectomi
high
risk
develop
bronchial
asthma
crohn
diseas
azt
penetr
cell
membran
concentr
within
lysosom
compart
wide
distribut
whole
bodi
achiev
higher
concentr
tissu
thu
serum
deliveri
infect
tissu
enhanc
inflammatori
process
azt
use
rheumat
fever
prevent
long
time
studi
adopt
new
regiemen
prevent
recurr
tonsil
pediatr
patient
receiv
mgkg
prophylact
dose
azt
divid
consecut
day
everi
month
consecut
month
patient
receiv
azt
alon
signific
less
tonsil
attack
less
sever
symptom
patient
nt
receiv
prophylaxi
period
studi
el
hennawi
et
al
studi
conclud
azt
effect
prophylaxi
recurr
tonsil
great
benefit
better
qol
compar
patient
tonsillectomi
howev
use
prophylact
regimen
rheumat
fever
prevent
weekli
azt
nt
includ
control
group
studi
casey
pichichero
report
azt
treatment
gabh
tonsillopharyng
children
adult
effect
treatment
regimen
provid
clinic
cure
tonsillopharyng
report
patient
establish
rheumat
heart
diseas
recurr
tonsil
weekli
azt
dose
studi
patient
still
tonsil
attack
azt
use
azt
fail
prevent
tonsil
complet
clear
one
possibl
drug
dosag
wide
space
though
azt
long
halflif
drug
concentr
might
adequ
azt
administ
mgkg
per
cours
ie
mgkg
day
mgkg
day
day
children
superior
cours
penicillin
howev
azt
regimen
inferior
regimen
also
mgkg
per
cours
inferior
cours
penicillin
azt
treatment
may
requir
higher
dose
longer
durat
effect
recurr
tonsil
prevent
use
mgkg
prophylact
dose
divid
possibl
azt
failur
may
due
poor
patient
complianc
failur
drug
reach
adequ
concentr
mucosa
microbi
toler
azt
recurr
exposur
patient
virul
strain
gabh
suppress
natur
immun
disturb
normal
flora
throat
azt
inhibit
growth
alpha
streptococci
normal
defend
pharyng
mucosa
pathogen
lower
mic
intracellular
accumul
macrolid
shown
leucocyt
epitheli
cell
probabl
princip
cell
target
gabh
leucocyt
azt
accumul
predominantli
lysosom
wherea
intracellular
gabh
found
phagosom
cytosol
recent
studi
report
adult
patient
recurr
tonsil
may
higher
incid
humor
antibodi
defici
compar
age
sexmatch
control
point
use
echinacea
adjunct
azt
trial
enhanc
patient
immun
echinacea
also
known
purpl
coneflow
one
popular
herbal
studi
design
determin
effect
prophylact
regiemen
finit
period
focus
potenti
valu
ad
echinacea
azt
limit
studi
data
consequ
discontinu
continu
prophylact
cours
patient
gabh
tonsillopharyng
experi
clinic
improv
time
without
antibiot
therapi
therefor
measur
clinic
respons
treatment
larg
meaningless
antibiot
trial
complet
therapi
patient
experi
relaps
recurr
symptom
sign
tonsillopharyng
recoveri
gabh
cultur
throat
swab
sampl
howev
azt
dose
clinic
cure
bacteri
erad
rate
children
compar
penicillin
regimen
superior
discontinu
azt
cours
studi
open
new
era
research
illustr
possibl
consequ
prolong
therapi
infecti
cours
prophylaxi
discontinu
possibl
long
last
benefit
multipl
prophylact
cours
need
administ
main
strength
studi
prospect
studi
control
group
differ
clinic
characterist
use
prophylact
regimen
tabl
tabl
demograph
characterist
patient
studi
group
group
